Baseline variable | Conservative: csDMARD (n=330) | Early aggressive: cs+bDMARD (n=135) | |||
N | Mean±SD | N | Mean±SD | P value* | |
Age (years) | 330 | 9.81±5.08 | 135 | 10.24±4.74 | 0.40 |
Age of diagnosis (years) | 330 | 9.70±5.11 | 135 | 10.14±4.78 | 0.39 |
Year of diagnosis | 330 | 2013.57±3.14 | 135 | 2013.12±2.88 | 0.15 |
Onset age (years) | 265 | 8.18±4.86 | 110 | 8.77±5.04 | 0.29 |
Disease duration at diagnosis (years) | 266 | 1.40±2.24 | 109 | 1.66±2.97 | 0.35 |
Time since diagnosis (years) | 330 | 0.11±0.16 | 135 | 0.09±0.16 | 0.36 |
cJADAS10 (0–30) | 203 | 12.39±5.91 | 92 | 16.08±7.14 | <0.0001 |
Active joint count (0–71) | 296 | 7.53±8.87 | 127 | 11.97±11.77 | <0.0001 |
Patient/parent global assessment of well-being (0–10) | 294 | 3.39±2.46 | 122 | 4.54±2.69 | <0.0001 |
Physician global assessment (0–10) | 221 | 4.14±2.45 | 98 | 5.08±2.68 | 0.002 |
Limited range of motion (0–71) | 296 | 5.51±7.27 | 127 | 9.33±11.30 | <0.0001 |
Erythrocyte sedimentation rate (mm/h) | 175 | 19.79±19.54 | 85 | 32.33±29.39 | <0.0001 |
Global pain NRS (0–10) | 298 | 4.15±2.71 | 124 | 5.12±2.65 | 0.0008 |
PedsQL generic total | 165 | 67.58±17.53 | 67 | 61.35±19.24 | 0.018 |
bDMARD, biologic disease-modifying antirheumatic drug; cJADAS, clinical Juvenile Arthritis Disease Activity Score; csDMARD, conventional synthetic disease-modifying antirheumatic drug; NRS, Numerical Rating Scale; PedsQL, Pediatric Quality of Life Inventory.